Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 Oct;43(2):563-571.
doi: 10.1007/s12028-025-02254-9. Epub 2025 Apr 25.

Intrathecal Dexamethasone as a FIRES Extinguisher: A 12-Patient Clinical Experience with Usage of Intrathecal Dexamethasone for Febrile Infection-Related Epilepsy Syndrome

Raquel Farias-Moeller #  1 , Aurélie Hanin #  2   3   4 , Sadaf Ahsan  5 , John Brooks  6 , Scott D Caganap  7 , Barry Czeisler  7 , Emmanuel Cheuret  8 , Brianna Cocuzzo  9 , Cecil D Hahn  10 , Henrik Kyureghyan  11 , Marie-Odile Marcoux  12 , Rana Mohamed  5 , Carol Park  13 , Michal Stern Zimmer  10 , Vivek Barun  14 , Yi Chen Lai  15 , Lawrence J Hirsch  16
Affiliations
Multicenter Study

Intrathecal Dexamethasone as a FIRES Extinguisher: A 12-Patient Clinical Experience with Usage of Intrathecal Dexamethasone for Febrile Infection-Related Epilepsy Syndrome

Raquel Farias-Moeller et al. Neurocrit Care. 2025 Oct.

Abstract

Background: New-onset refractory status epilepticus (NORSE) is a devastating condition with high mortality and poor long-term outcomes. Febrile infection-related epilepsy syndrome (FIRES) is a subset of NORSE, preceded by fever. Intrathecal dexamethasone (IT-DEX) has emerged as a potential treatment, but few cases have been reported. This study aims to describe the use of IT-DEX in NORSE/FIRES, focusing on treatment logistics, dosing strategies, and patient outcomes.

Methods: We conducted a retrospective analysis of 12 patients (10 children and 2 adults) with NORSE (including FIRES) enrolled in an international multicenter clinical biorepository who received IT-DEX as part of their treatment. Demographic and clinical data were extracted. IT-DEX pharmacological details and administration logistics were collected by contacting the primary investigators. A descriptive analysis was performed to evaluate treatment timing, dosage, and concurrent management, as well as clinical outcomes and cytokine profiles.

Results: All patients qualified as FIRES. Patients were treated with a median of five doses of IT-DEX, starting a median of 20 days after refractory status epilepticus onset, with a median dose per infusion of 5 mg (0.21 mg/kg/dose). Clinicians reported a perceived favorable effect on seizure control in 83% of cases, with a median delay of 5 days to wean off continuous infusions after the last IT-DEX administration. Cytokine analysis (based on data from four patients with serial cerebrospinal fluid measurements and two patients with serial blood measurements) revealed persistently elevated levels of proinflammatory markers in most patients, with no significant changes following IT-DEX administration. No adverse effects were reported.

Conclusions: Most clinicians perceived a favorable effect of IT-DEX in refractory status epilepticus termination, and its use appears to be safe in patients with FIRES. This study provides a detailed description of administration logistics and dosing strategies from an international multicenter cohort. Additional studies are needed to confirm the safety and efficacy of IT-DEX and determine its impact on long-term outcomes including epilepsy prevention and functional recovery.

Keywords: Febrile infection-related epilepsy syndrome; Intrathecal dexamethasone; New-onset refractory status epilepticus; Outcomes.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: Dr. Hirsch received support for investigator-initiated studies from the Daniel Raymond Wong Neurology Research Fund and the NORSE/FIRES Research Fund at Yale. Dr. Hanin received postdoctoral grants from the Paratonnerre Association, the Swebilius Foundation, the Servier Institute, and the Philippe Foundation for NORSE-related research. Dr. Farias-Moeller, Dr. Hanin, Dr. Lai, and Dr. Hirsch are members of the Medical and Scientific Advisory Board of the NORSE Institute. Ethical Approval/Informed Consent: We confirm adherence to ethical guidelines, and we indicate ethical approvals and use of informed consent, as appropriate.

References

    1. Hirsch LJ, Gaspard N, van Baalen A, Nabbout R, Demeret S, Loddenkemper T, et al. Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions. Epilepsia. 2018;59:739–44. - DOI - PubMed
    1. Gaspard N, Foreman BP, Alvarez V, Cabrera Kang C, Probasco JC, Jongeling AC, et al. New-onset refractory status epilepticus: etiology, clinical features, and outcome. Neurology. 2015;85:1604–13. - DOI - PubMed - PMC
    1. Sculier C, Barcia Aguilar C, Gaspard N, Gaínza-Lein M, Sánchez Fernández I, Amengual-Gual M, et al. Clinical presentation of new onset refractory status epilepticus in children (the pSERG cohort). Epilepsia. 2021;62:1629–42. - DOI - PubMed - PMC
    1. Wu J, Lan X, Yan L, Hu Y, Hong S, Jiang L, et al. A retrospective study of 92 children with new-onset refractory status epilepticus. Epilepsy Behav. 2021;125: 108413. - DOI - PubMed
    1. Sculier C, Gaspard N. New-onset refractory status epilepticus and febrile infection-related epilepsy syndrome. Curr Opin Neurol. 2023;36:110–6. - DOI - PubMed

Publication types

LinkOut - more resources